CTXR
Citius Pharmaceuticals, Inc. [CTXR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CTXR Stock Summary
Top 10 Correlated Stocks
CTXR
In the News
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, has rescheduled its participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for the late Howard Safir, a long-time member of the Citius Board.
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023.
Citius Pharmaceuticals: Steer Clear From This One
The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2023 PDUFA; it has generated excitement among investors, although it is unlikely to generate alpha. Its second lead therapy is likely to disappoint.
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days
Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway far enough to reach commercialization of its major products, and are therefore a "must complete" by the company.
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
UPDATED: Chairman & CEO of Citius, Leonard Mazur, to present September 12, 2022 at 8:30am ET CRANFORD, N.J. , Sept. 8, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C.
Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated.
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
CRANFORD, N.J. , May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C.
3 Reddit Stocks to Buy in May
These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond The post 3 Reddit Stocks to Buy in May appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.
CTXR Financial details
CTXR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-09-30
| Metric | History | 2018-09-30 | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.17 | -0.77 | -0.45 | -0.21 | -0.23 | |
| Operating cash flow per share | -1.05 | -0.62 | -0.43 | -0.22 | -0.19 | |
| Free cash flow per share | -1.05 | -0.62 | -0.43 | -0.59 | -0.19 | |
| Cash per share | 0.86 | 0.39 | 0.35 | 0.65 | 0.29 | |
| Book value per share | 2.6 | 1.21 | 0.86 | 1.22 | 0.7 | |
| Tangible book value per share | 0.64 | 0.17 | 0.13 | 0.59 | 0.24 | |
| Share holders equity per share | 2.6 | 1.21 | 0.86 | 1.22 | 0.7 | |
| Interest debt per share | 0.02 | 0.01 | 0.03 | 0.01 | 0.01 | |
| Market cap | 17.92M | 15.27M | 40.73M | 220.46M | 176.76M | |
| Enterprise value | 8.91M | 7.55M | 28.22M | 151.24M | 135.73M | |
| P/E ratio | -1.43 | -0.98 | -2.3 | -9.53 | -5.25 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.58 | -1.23 | -2.41 | -9.09 | -6.23 | |
| PFCF ratio | -1.58 | -1.23 | -2.41 | -3.43 | -6.23 | |
| P/B Ratio | 0.64 | 0.63 | 1.21 | 1.67 | 1.72 | |
| PTB ratio | 0.64 | 0.63 | 1.21 | 1.67 | 1.72 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -0.71 | -0.49 | -1.62 | -6.56 | -4.13 | |
| EV to operating cash flow | -0.79 | -0.61 | -1.67 | -6.24 | -4.79 | |
| EV to free cash flow | -0.79 | -0.61 | -1.67 | -2.35 | -4.79 | |
| Earnings yield | -0.7 | -1.02 | -0.43 | -0.1 | -0.19 | |
| Free cash flow yield | -0.63 | -0.81 | -0.42 | -0.29 | -0.16 | |
| Debt to equity | 0.01 | 0.01 | 0.04 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.03 | 0.01 | 0.01 | |
| Net debt to EBITDA | 0.72 | 0.5 | 0.72 | 3 | 1.25 | |
| Current ratio | 3.16 | 1.72 | 3.41 | 18.28 | 9.84 | |
| Interest coverage | -870.64 | -948.63 | -1.13K | -2.17K | -132.52 | |
| Income quality | 0.9 | 0.8 | 0.96 | 1.05 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.68 | 0.72 | 0.66 | 0.48 | 0.6 | |
| Capex to operating cash flow | 0 | 0 | 0 | 1.65 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | -0.01 | -242.66 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.26 | 4.58 | 2.95 | 2.41 | 1.91 | |
| ROIC | -0.54 | -0.64 | -0.49 | -0.18 | -0.33 | |
| Return on tangible assets | -1.25 | -1.95 | -1.18 | -0.31 | -0.74 | |
| Graham Net | 0.62 | 0.16 | 0.1 | 0.56 | 0.21 | |
| Working capital | 6.88M | 3.33M | 9.88M | 68.83M | 40.03M | |
| Tangible asset value | 6.88M | 3.39M | 4.92M | 64.04M | 34.68M | |
| Net current asset value | 6.88M | 3.33M | 3.88M | 63.17M | 33.99M | |
| Invested capital | 0.01 | 0.01 | 0.04 | 0.01 | 0.01 | |
| Average receivables | 409.17K | 409.17K | 0 | 0 | 0 | |
| Average payables | 1.09M | 2.14M | 2.28M | 1.57M | 1.22M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.45 | -0.64 | -0.52 | -0.17 | -0.33 | |
| Capex per share | 0 | 0 | 0 | -0.37 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q3
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.06 | -73.31K | -0.02 | -0.07 | -0.06 | |
| Operating cash flow per share | -0.05 | -58.1K | -0.03 | -0.05 | -0.06 | |
| Free cash flow per share | -0.05 | -58.1K | -0.03 | -0.05 | -0.06 | |
| Cash per share | 0.33 | 382.68K | 0.25 | 0.2 | 0.22 | |
| Book value per share | 0.75 | 943.36K | 0.69 | 0.62 | 0.64 | |
| Tangible book value per share | 0.28 | 318.16K | 0.22 | 0.16 | 0.19 | |
| Share holders equity per share | 0.75 | 943.36K | 0.69 | 0.62 | 0.64 | |
| Interest debt per share | 0.01 | 7.46K | -0.02 | 0 | 0 | |
| Market cap | 134.44M | 131.89 | 115.51M | 171.11M | 184.53M | |
| Enterprise value | 87.12M | -41.03M | 79.25M | 142.63M | 151.78M | |
| P/E ratio | -3.81 | 0 | -8.04 | -4.06 | -5.44 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -17.43 | 0 | -23.94 | -21.79 | -19.26 | |
| PFCF ratio | -17.43 | 0 | -23.94 | -21.79 | -19.26 | |
| P/B Ratio | 1.23 | 0 | 1.15 | 1.88 | 1.89 | |
| PTB ratio | 1.23 | 0 | 1.15 | 1.88 | 1.89 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -9.88 | 5.57 | -11 | -13.41 | -17.6 | |
| EV to operating cash flow | -11.3 | 6.48 | -16.43 | -18.16 | -15.84 | |
| EV to free cash flow | -11.3 | 6.48 | -16.43 | -18.16 | -15.84 | |
| Earnings yield | -0.07 | -60.59K | -0.03 | -0.06 | -0.05 | |
| Free cash flow yield | -0.06 | -48.01K | -0.04 | -0.05 | -0.05 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Net debt to EBITDA | 5.37 | 5.57 | 5.03 | 2.68 | 3.8 | |
| Current ratio | 11.4 | 9.84 | 9.33 | 5.62 | 7.1 | |
| Interest coverage | -168.18 | -55.99 | 1.91 | 35.23 | 0 | |
| Income quality | 0.87 | 0.79 | 1.34 | 0.75 | 1.13 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.57 | 0.6 | 0.62 | 0.66 | 0.62 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.01 | 1.25M | 0.62 | 1 | 0.89 | |
| ROIC | -0.08 | -0.08 | -0.07 | -0.12 | -0.09 | |
| Return on tangible assets | -0.17 | -0.18 | -0.08 | -0.3 | -0.2 | |
| Graham Net | 0.26 | 285.68K | 0.18 | 0.11 | 0.14 | |
| Working capital | 46.37M | 40.03M | 37.78M | 28.69M | 35.32M | |
| Tangible asset value | 41.59M | 34.68M | 32.29M | 23.06M | 29.55M | |
| Net current asset value | 40.85M | 33.99M | 31.65M | 22.47M | 29.01M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.7M | 1.43M | 1.35M | 2.13M | 2.9M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.08 | -0.08 | -0.04 | -0.12 | -0.09 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CTXR Frequently Asked Questions
What is Citius Pharmaceuticals, Inc. stock symbol ?
Citius Pharmaceuticals, Inc. is a US stock , located in Cranford of Nj and trading under the symbol CTXR
What is Citius Pharmaceuticals, Inc. stock quote today ?
Citius Pharmaceuticals, Inc. stock price is $0.7653 today.
Is Citius Pharmaceuticals, Inc. stock public?
Yes, Citius Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 650.97K
- Market Capitalization 125.48M
- Employee 21
- CEO Mr. Leonard L. Mazur
- Headquarters Cranford,NJ,US
- IPO Date 2014-10-02
-
Website
https://www.citiuspharma.com 
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
